Novel chimeric genotype 1b/2a hepatitis C virus suitable for high-throughput screening

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 2, 2008, Pages 666-674

  Zhang, Yingjia ^a   Weady, Peter ^a   Duggal, Rohit ^a   Hao, Weidong ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD81 ANTIGEN; CHIMERIC PROTEIN; CILUPREVIR; LUCIFERASE; MONOCLONAL ANTIBODY; VIRUS PROTEIN; VIRUS RNA;

ARTICLE; CELL CULTURE; CELL STRAIN; CHIMERA; CONTROLLED STUDY; GENETIC TRANSFECTION; GENOTYPE; HEPATITIS C VIRUS; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; LIFE CYCLE; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PRIORITY JOURNAL; RENILLA; REPLICON; REPORTER GENE; RNA REPLICATION; VIRUS ENTRY; VIRUS GENOME; VIRUS PARTICLE;

ANTIVIRAL AGENTS; CELL LINE; GENES, REPORTER; GENOTYPE; HEPACIVIRUS; HUMANS; LUCIFERASES; MICROBIAL SENSITIVITY TESTS; RECOMBINATION, GENETIC; RNA, VIRAL; VIRION; VIRUS REPLICATION;

EID: 38649097542     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01133-07     Document Type: Article

References (29)

1. Akazawa, D., T. Date, K. Morikawa, A. Murayama, M. Miyamoto, M. Kaga, H. Barth, T. F. Baumert, J. Dubuisson, and T. Wakita. 2007. CD81 expression is important for the permissiveness of Huh7 cell clones for heterogeneous hepatitis C virus infection. J. Virol. 81:5036-5045.
2. Alter, M. J., D. Kruszon-Moran, O. V. Nainan, G. M. McQuillan, F. Gao, L. A. Moyer, R. A. Kaslow, and H. S. Margolis. 1999. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N. Engl. J. Med. 341:556-562.
3. Bartenschlager, R. 2002. Hepatitis C virus replicons: potential role for drug development. Nat. Rev. Drug Discov. 1:911-916.
4. Bartosch, B., J. Dubuisson, and F. L. Cosset. 2003. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J. Exp. Med. 197:633-642.
5. Camp, D., C. Matthews, S. Neville, M. Rouns, R. Scott, and T. Truong. 2006. Development of a synthetic process towards a hepatitis C polymerase inhibitor. Org. Process Res. 10:814-821.
6. Chinnasamy, D., M. D. Milsom, J. Shaffer, J. Neuenfeldt, A. F. Shaaban, G. P. Margison, L. J. Fairbairn, and N. Chinnasamy. 2006. Multicistronic lentiviral vectors containing the FMDV 2A cleavage factor demonstrate robust expression of encoded genes at limiting MOI. Virol. J. 3:14.
7. Finley, D., and V. Chau. 1991. Ubiquitination. Annu. Rev. Cell Biol. 7:25-69.
8. Frese, M., K. Barth, A. Kaul, V. Lohmann, V. Schwarzle, and R. Bartenschlager. 2003. Hepatitis C virus RNA replication is resistant to tumour necrosis factor-alpha. J. Gen. Virol. 84:1253-1259.
9. Hao, W., K. J. Herlihy, N. J. Zhang, S. A. Fuhrman, C. Doan, A. K. Patick, and R. Duggal. 2007. Development of a novel dicistronic reporter-selectable hepatitis C virus replicon suitable for high-throughput inhibitor screening. Antimicrob. Agents Chemother. 51:95-102.
10. Hershko, A. 1991. The ubiquitin pathway for protein degradation. Trends Biochem. Sci. 16:265-268.
11. Hugle, T., and A. Cerny. 2003. Current therapy and new molecular approaches to antiviral treatment and prevention of hepatitis C. Rev. Med. Virol. 13:361-371.
12. Kato, T., T. Date, M. Miyamoto, A. Furusaka, K. Tokushige, M. Mizokami, and T. Wakita. 2003. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology 125:1808-1817.
13. Kaul, A., I. Worz, T. Pietschmann, A. Shavinskaya, and R. Bartenschlager. 2006. Adaptation of authentic and chimeric hepatitis C virus to a human hepatoma cell line, abstr. 219. Abstr. 13th International Meeting on Hepatitis C Virus and Related Viruses, Cairns, Queensland, Australia, 27 to 31 August, 2006.
14. Krieger, N., V. Lohmann, and R. Bartenschlager. 2001. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J. Virol. 75:4614-4624.
15. Lake-Bakaar, G. 2003. Current and future therapy for chronic hepatitis C virus liver disease. Curr. Drug Targets Infect. Disord. 3:247-253.
16. Lamarre, D., P. C. Anderson, M. Bailey, P. Beaulieu, G. Bolger, P. Bonneau, M. Bos, D. R. Cameron, M. Cartier, M. G. Cordingley, A. M. Faucher, N. Goudreau, S. H. Kawai, G. Kukolj, L. Lagace, S. R. LaPlante, H. Narjes, M. A. Poupart, J. Rancourt, R. E. Sentjens, R. St George, B. Simoneau, G. Steinmann, D. Thibeault, Y. S. Tsantrizos, S. M. Weldon, C. L. Yong, and M. Llinas-Brunet. 2003. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426:186-189.
17. Lindenbach, B. D., M. J. Evans, A. J. Syder, B. Wolk, T. L. Tellinghuisen, C. C. Liu, T. Maruyama, R. O. Hynes, D. R. Burton, J. A. McKeating, and C. M. Rice. 2005. Complete replication of hepatitis C virus in cell culture. Science 309:623-626.
18. Lohmann, V., F. Korner, J. Koch, U. Herian, L. Theilmann, and R. Bartenschlager. 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285:110-113.
19. Milsom, M. D., L. B. Woolford, G. P. Margison, R. K. Humphries, and L. J. Fairbairn. 2004. Enhanced in vivo selection of bone marrow cells by retroviral-mediated coexpression of mutant 06-methylguanine-DNA- methyltransferase and HOXB4. Mol. Ther. 10:862-873.
20. Pietschmann, T., A. Kaul, G. Koutsoudakis, A. Shavinskaya, S. Kallis, E. Steinmann, K. Abid, F. Negro, M. Dreux, F. L. Cosset, and R. Bartenschlager. 2006. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc. Natl. Acad. Sci. USA 103:7408-7413.
21. Pietschmann, T., V. Lohmann, A. Kaul, N. Krieger, G. Rinck, G. Rutter, D. Strand, and R. Bartenschlager. 2002. Persistent and transient replication of full-length hepatitis C virus genomes in cell culture. J. Virol. 76:4008-4021.
22. Pileri, P., Y. Uematsu, S. Campagnoli, G. Galli, F. Falugi, R. Petracca, A. J. Weiner, M. Houghton, D. Rosa, G. Grandi, and S. Abrignani. 1998. Binding of hepatitis C virus to CD81. Science 282:938-941.
23. Rouille, Y., F. Helle, D. Delgrange, P. Roingeard, C. Voisset, E. Blanchard, S. Belouzard, J. McKeating, A. H. Patel, G. Maertens, T. Wakita, C. Wychowski, and J. Dubuisson. 2006. Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus. J. Virol. 80:2832-2841.
24. Ryan, M. D., A. M. King, and G. P. Thomas. 1991. Cleavage of foot-and-mouth disease virus polyprotein is mediated by residues located within a 19 amino acid sequence. J. Gen. Virol. 72:2727-2732.
25. Schaller, T., N. Appel, G. Koutsoudakis, S. Kallis, V. Lohmann, T. Pietschmann, and R. Bartenschlager. 2007. Analysis of hepatitis C virus superinfection exclusion by using novel fluorochrome gene-tagged viral genomes. J. Virol. 81:4591-4603.
26. Wakita, T., T. Pietschmann, T. Kato, T. Date, M. Miyamoto, Z. Zhao, K. Murthy, A. Habermann, H. G. Krausslich, M. Mizokami, R. Bartenschlager, and T. J. Liang. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11:791-796.
27. World Health Organization. 2000. Hepatitis C fact sheet 164. http://www.who.int/mediacentre/factsheets/fs164/en.
28. Yi, M., Y. Ma, J. Yates, and S. M. Lemon. 2007. Compensatory mutations in E1, p7, NS2, and NS3 enhance yields of cell culture-infectious intergenotypic chimeric hepatitis C virus. J. Virol. 81:629-638.
29. Zhong, J., P. Gastaminza, G. Cheng, S. Kapadia, T. Kato, D. R. Burton, S. F. Wieland, S. L. Uprichard, T. Wakita, and F. V. Chisari. 2005. Robust hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. USA 102:9294-9299.